Literature DB >> 10455485

Biotin production under limiting growth conditions by Agrobacterium/Rhizobium HK4 transformed with a modified Escherichia coli bio operon.

.   

Abstract

The E. coli biotin (bio) operon was modified to improve biotin production by host cells: (a) the divergently transcribed wild-type bio operon was re-organized into one transcriptional unit; (b) the wild-type bio promoter was replaced with a strong artificial (tac) promoter; (c) a potential stem loop structure between bioD and bioA was removed; and (d) the wild-type bioB ribosomal binding site (RBS) was replaced with an artificial RBS that resulted in improved bioB expression. The effects of the modifications on the bio operon were studied in E. coli by measuring biotin and dethiobiotin production, and bio gene expression with mini-cells and two-dimensional polyacrylamide gel electrophoresis. The modified E. coli bio operon was introduced into a broad host-range plasmid and used to transform Agrobacterium/Rhizobium HK4, which then produced 110 mg L-1 of biotin in a 2-L fermenter, growing on a defined medium with diaminononanoic acid as the starting material. Biotin production was not growth-phase dependent in this strain, and the rate of production remained high under limiting (maintenance) and zero growth conditions.

Entities:  

Year:  1999        PMID: 10455485     DOI: 10.1038/sj.jim.2900669

Source DB:  PubMed          Journal:  J Ind Microbiol Biotechnol        ISSN: 1367-5435            Impact factor:   3.346


  2 in total

1.  Development of biotin-prototrophic and -hyperauxotrophic Corynebacterium glutamicum strains.

Authors:  Masato Ikeda; Aya Miyamoto; Sumire Mutoh; Yuko Kitano; Mei Tajima; Daisuke Shirakura; Manami Takasaki; Satoshi Mitsuhashi; Seiki Takeno
Journal:  Appl Environ Microbiol       Date:  2013-05-24       Impact factor: 4.792

2.  Transfer of the high-GC cyclohexane carboxylate degradation pathway from Rhodopseudomonas palustris to Escherichia coli for production of biotin.

Authors:  Jeffrey R Bernstein; Thomas Bulter; James C Liao
Journal:  Metab Eng       Date:  2008-02-13       Impact factor: 9.783

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.